Cancer test boosts market hopes for Proteomics – The West Australian

The result was welcomed by the Perth-based medical technology company as an “exciting milestone” in its pursuit of an accurate, easy-to-use and non-invasive blood test to diagnose the disease.

Proteomics analysed samples from a development cohort of 253 people and then tested the performance of its statistical models in a validation cohort of 49 patient samples from New Orleans, USA. However, Proteomics cautions that because of the cohort size of the study and its relatively small validation cohort size, further work is needed to confirm the statistical significance of the results.

Article: Cancer test boosts market hopes for Proteomics


  • This field is for validation purposes and should be left unchanged.